The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
Open accessAbstract
Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human liver. Expression is highly variable both between individuals and within individuals, owing to non-genetic factors, genetic polymorphisms, inducibility, and irreversible inhibition by many compounds. Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. CYP2B6 is one of the most polymorphic CYP genes in humans and variants have been shown to affect transcriptional regulation, splicing, mRNA and protein expression, and catalytic activity. Some variants appear to affect several functional levels simultaneously, thus, combined in haplotypes, leading to complex interactions between substrate-dependent and -independent mechanisms. The most common functionally deficient allele is CYP2B6*6 [Q172H, K262R], which occurs at frequencies of 15 to over 60% in different populations. The allele leads to lower expression in liver due to erroneous splicing. Recent investigations suggest that the amino acid changes contribute complex substrate-dependent effects at the activity level, although data from recombinant systems used by different researchers are not well in agreement with each other. Another important variant, CYP2B6*18 [I328T], occurs predominantly in Africans (4-12%) and does not express functional protein. A large number of uncharacterized variants are currently emerging from different ethnicities in the course of the 1000 Genomes Project. The CYP2B6 polymorphism is clinically relevant for HIV-infected patients treated with the reverse transcriptase inhibitor efavirenz, but it is increasingly being recognized for other drug substrates. This review summarizes recent advances on the functional and clinical significance of CYP2B6 and its genetic polymorphism, with particular emphasis on the comparison of kinetic data obtained with different substrates for variants expressed in different recombinant expression systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C., & Acosta, E. P. (2004) · PubMed · Cited by 627
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Self-citationInhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Chang, T. K. H., Weber, G. F., Crespi, C. L., & Waxman, D. J. (1993) · PubMed · Cited by 545
Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., Fackenthal, J. D., Rogan, P. K., Ring, B., Wrighton, S. A., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054866 · Cited by 400
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor
Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., & Kliewer, S. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12603-x · Cited by 374
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Cytochrome P450-mediated metabolism in the human gut wall
Thelen, K., & Dressman, J. B. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338
CYP2B6: New Insights into a Historically Overlooked Cytochrome P450 Isozyme
Wang, H., & Tompkins, L. M. (2008) · Current Drug Metabolism · doi:10.2174/138920008785821710 · Cited by 299
Faucette, S. R., Zhang, T.-C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., & Wang, H. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112136 · Cited by 294
Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., & Keirns, J. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14960-4 · Cited by 277
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver
Yang, X., Zhang, B., Molony, C., Chudin, E., Hao, K., Zhu, J., Gaedigk, A., Suver, C., Zhong, H., Leeder, J. S., et al. (2010) · Genome Research · doi:10.1101/gr.103341.109 · Cited by 271
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Self-citationHuman CYP2B6: expression, inducibility and catalytic activities
Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P., & de Waziers, I. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00004 · Cited by 265
Huang, Z., Roy, P., & Waxman, D. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00410-4 · Cited by 263
Polymorphic CYP2B6: Molecular Mechanisms and Emerging Clinical Significance
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., H Hofmann, M., & Schwab, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.743 · Cited by 258
Self-citationRotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100072 · Cited by 257
Self-citationEap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Déglon, J.-J., Besson, J., Croquette-Krokar, M., Carrupt, P.-A., & Abriel, H. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100120 · Cited by 255
Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues
Choudhary, D., Jansson, I., Schenkman, J. B., Sarfarazi, M., & Stoilov, I. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00174-7 · Cited by 252
Fuhr, U., Jetter, A., & Kirchheiner, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100050 · Cited by 245
Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K. H., & Waxman, D. J. (1997) · PubMed · Cited by 245
Cytochrome P450 enzymes in the brain: emerging evidence of biological significance
Ferguson, C. S., & Tyndale, R. F. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.08.005 · Cited by 242
Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes
Yamazaki, H., Inoue, K., Hashimoto, M., & Shimada, T. (1999) · Archives of Toxicology · doi:10.1007/s002040050588 · Cited by 235
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
CRETTOL, S., DEGLON, J., BESSON, J., CROQUETTEKROKKAR, M., GOTHUEY, I., HAMMIG, R., MONNAT, M., HUTTEMANN, H., BAUMANN, P., & EAP, C. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.011 · Cited by 228
Burk, O., Arnold, K. A., Nussler, A. K., Schaeffeler, E., Efimova, E., Avery, B. A., Avery, M. A., Fromm, M. F., & Eichelbaum, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009019 · Cited by 224
Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., Fujimoto, K., Sato, I., Ueda, M., Horiba, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522175 · Cited by 223
Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolism in Vitro
Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., Flockhart, D. A., & Zanger, U. M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.547 · Cited by 222
Self-citationRibaudo, H. J., Haas, D. W., Tierney, C., Kim, R. B., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Marzolini, C., Fletcher, C. V., Tashima, K. T., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/499364 · Cited by 221
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
Xie, H.-J., Yasar, Ü., Lundgren, S., Griskevicius, L., Terelius, Y., Hassan, M., & Rane, A. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500157 · Cited by 215
Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., & LeCluyse, E. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212482200 · Cited by 215
Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133306 · Cited by 210
Self-citationBurger, D., Van Der Heiden, I., La Porte, C., Van Der Ende, M., Groeneveld, P., Richter, C., Koopmans, P., Kroon, F., Sprenger, H., Lindemans, J., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02536.x · Cited by 209
Nyakutira, C., Röshammar, D., Chigutsa, E., Chonzi, P., Ashton, M., Nhachi, C., & Masimirembwa, C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0412-3 · Cited by 208
Court, M. H., Duan, S. X., Hesse, L. M., Venkatakrishnan, K., & Greenblatt, D. J. (2001) · Anesthesiology · doi:10.1097/00000542-200101000-00021 · Cited by 207
Svensson, & Ashton (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00044.x · Cited by 205
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain
Miksys, S. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00136-9 · Cited by 199
Kreth, K.-P., Kovar, K.-A., Schwab, M., & Zanger, U. M. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00284-7 · Cited by 198
Self-citationHesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2004) · Pharmacogenetics · doi:10.1097/00008571-200404000-00002 · Cited by 193
Role of CYP2B6 in Stereoselective Human Methadone Metabolism
Totah, R. A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K., & Kharasch, E. D. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181642938 · Cited by 192
Bray, J., Sludden, J., Griffin, M. J., Cole, M., Verrill, M., Jamieson, D., & Boddy, A. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605587 · Cited by 183
CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS
Roy, J.-N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J., & Roger, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.003822 · Cited by 182
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Faucette, S. R., Wang, H., Hamilton, G. A., Jolley, S. L., Gilbert, D., Lindley, C., Yan, B., Negishi, M., & LeCluyse, E. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.348 · Cited by 179
Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6
Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V., & Wrighton, S. A. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37719-5 · Cited by 178
THE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*
EKINS, S., & WRIGHTON, S. A. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101942 · Cited by 176
TURPEINEN, M., TOLONEN, A., UUSITALO, J., JALONEN, J., PELKONEN, O., & LAINE, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.010 · Cited by 163
Yuan, J., Guo, S. J., Hall, D. B., Cammett, A. M., Jayadev, S., Distel, M., Storfer, S. P., Huang, Z., Mootsikapun, P., Ruxrungtham, K., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834779df · Cited by 159
Jeong, S., Nguyen, P. D., & Desta, Z. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01123-08 · Cited by 155
Functional Characterization of Cytochrome P450 2B6 Allelic Variants
Jinno, H., Tanaka‐Kagawa, T., Ohno, A., Makino, Y., Matsushima, E., Hanioka, N., & Ando, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.398 · Cited by 152
Expression and Function of Cytochrome P450 in Brain Drug Metabolism
Meyer, R., Gehlhaus, M., Knoth, R., & Volk, B. (2007) · Current Drug Metabolism · doi:10.2174/138920007780655478 · Cited by 145
Holzinger, E. R., Grady, B. J., Ritchie, M. D., Ribaudo, H. J., Acosta, E. P., Morse, G. D., Gulick, R. M., Robbins, G. K., Clifford, D. B., Daar, E. S., et al. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835a450b · Cited by 143
Ariyoshi, N., Miyazaki, M., Toide, K., Sawamura, Y.-I., & Kamataki, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4524 · Cited by 140
Dutheil, F., Beaune, P. H., & Loriot, M. (2007) · Biochimie · doi:10.1016/j.biochi.2007.10.007 · Cited by 139
Efavirenz in the therapy of HIV infection
Rakhmanina, N. Y., & van den Anker, J. N. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903483207 · Cited by 139
Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19
Hoffman, S. M. G., Nelson, D. R., & Keeney, D. S. (2001) · Pharmacogenetics · doi:10.1097/00008571-200111000-00007 · Cited by 138
Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M. G., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 138
Self-citationRibaudo, H. J., Liu, H., Schwab, M. G., Schaeffeler, E., Eichelbaum, M. F., Motsinger‐Reif, A. A., Ritchie, M. D., Zanger, U. M., Acosta, E. P., Morse, G. D., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/655470 · Cited by 137
Self-citationPharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers
Hsyu, P., Singh, A. K., Giargiari, T. D., Dunn, J. A., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04361.x · Cited by 137
Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay
Turpeinen, M., Uusitalo, J., Jalonen, J. E., & Olavi, P. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.10.006 · Cited by 137
Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Mo, S., Liu, Y.-H., Duan, W., Wei, M. Q., Kanwar, J. R., & Zhou, S.-F. (2009) · Current Drug Metabolism · doi:10.2174/138920009789895534 · Cited by 137
The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals
Hodgson, E., & Rose, R. L. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.10.002 · Cited by 134
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine
Oscarson, M., Zanger, U. M., Rifki, O. F., KLEIN, K., Eichelbaum, M. F., & Meyer, U. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.013 · Cited by 134
Self-citationNakajima, M., Komagata, S., Fujiki, Y., KANADA, Y., Ebi, H., Itoh, K., Mukai, H., Yokoi, T., & Minami, H. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328045c4fb · Cited by 133
Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068973 · Cited by 133
Self-citationYimer, G., Amogne, W., Habtewold, A., Makonnen, E., Ueda, N., Suda, A., Worku, A., Haefeli, W. E., Burhenne, J., Aderaye, G., et al. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.34 · Cited by 125
Penzak, S., Kabuye, G., Mugyenyi, P. N., Mbamanya, F., Natarajan, V., Alfaro, R., Kityo, C. M., Formentini, E., & Masur, H. (2007) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00432.x · Cited by 120
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9
Simonsson, U. S. H., Jansson, B., Hai, T. N., Huong, D. X., Tybring, G., & Ashton, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00092-4 · Cited by 119
Lubomirov, R., di Iulio, J., Fayet, A., Colombo, S. F., Martínez, R., Marzolini, C., Furrer, H., Vernazza, P., Calmy, A., Cavassini, M. L., et al. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328336eee4 · Cited by 116
Stereoselective and regiospecific hydroxylation of ketamine and norketamine
Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., Sanghvi, M., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2012) · Xenobiotica · doi:10.3109/00498254.2012.685777 · Cited by 114 · cited 2×
“, 2001) and ketamine (Desta et al., 2012), the analgesic pethidine (meperidine; Ramírez et al.”
BackgroundRae, J. M., Soukhova, N. V., Flockhart, D. A., & Desta, Z. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.525 · Cited by 113
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., Esser, S., Bogner, J. R., Brockmeyer, N. H., Bieniek, B., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr272 · Cited by 109
CYP2B6SNPs are associated with methadone dose required for effective treatment of opioid addiction
Levran, O., Peles, E., Hamon, S., Randesi, M., Adelson, M., & Kreek, M. J. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00349.x · Cited by 106
Zukunft, J., Lang, T., Richter, T., Hirsch‐Ernst, K. I., Nussler, A. K., Klein, K., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008086 · Cited by 105
Self-citationPharmacogenetics of cyclophosphamide in patients with hematological malignancies
Xie, H., Griškevičius, L., Ståhle, L., Hassan, Z., Yaşar, Ü., Rane, A., Broberg, U., Kimby, E. K., & Hassan, M. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.08.008 · Cited by 103
Cytochrome P450 2B6: function, genetics, and clinical relevance
Turpeinen, M., & Zanger, U. M. (2012) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2012-0027 · Cited by 100
Self-citationLubomirov, R., Colombo, S. F., di Iulio, J., Ledergerber, B., Martínez, R., Cavassini, M. L., Hirschel, B. J., Bernasconi, E., Elzi, L., Vernazza, P., et al. (2010) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq043 · Cited by 100
Involvement of human liver cytochrome P4502B6in the metabolism of propofol
Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., TANAKA, K. A., Funae, Y., Ishizaki, T., & Asada, A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.00344.x · Cited by 99
Human hepatic CYP2B6 developmental expression: The impact of age and genotype
Croom, E. L., Stevens, J. C., Hines, R. N., Wallace, A. D., & Hodgson, E. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.03.029 · Cited by 98
Feidt, D. M., Klein, K., Hofmann, U., Riedmaier, S., Knobeloch, D., Thasler, W. E., Weiß, T. S., Schwab, M. G., & Zanger, U. M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033886 · Cited by 96
Self-citationGay, S. C., Shah, M. B., Talakad, J. C., Maekawa, K., Roberts, A. G., Wilderman, P. R., Sun, L., Yang, J. Y., Huelga, S. C., Hong, W., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.062570 · Cited by 93
Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy
Sadée, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer, R. A., & Johnson, A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.314 · Cited by 89
Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., Takamiya, M., Aoki, Y., & Yokoi, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006254 · Cited by 86
Bumpus, N. N., Kent, U. M., & Hollenberg, P. F. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102525 · Cited by 77
Induction of the Unspecific Microsomal Hydroxylase in the Human Liver
Remmer, H., Schoene, B., Fleischmann, R., & Held, H. (2015) · KARGER eBooks · doi:10.1159/000394816 · Cited by 75
Mehlotra, R. K., Bockarie, M. J., & Zimmerman, P. A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02884.x · Cited by 74
Single‐Dose Pharmacokinetics of Bupropion in Adolescents: Effects of Smoking Status and Gender
Stewart, J. J., Berkel, H. J., Parish, R. C., Simar, M. R., Syed, A., Bocchini, J. A., Wilson, J. T., & Manno, J. E. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010564 · Cited by 74
Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole
Saußele, T., Burk, O., Blievernicht, J. K., Klein, K., Nussler, A. K., Nüssler, N. C., Hengstler, J. G., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100138 · Cited by 72
Self-citationEllison, C. A., Tian, Y., Knaak, J. B., Kostyniak, P. J., & Olson, J. R. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042572 · Cited by 72
Liu, P., Foster, G., LaBadie, R. R., Gutiérrez, M. J., & Sharma, A. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007309703 · Cited by 71
Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M. S., Johnson, M., Khoo, S., Back, D., & Owen, A. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00689.x · Cited by 70
Li, J., Ménard, V., Benish, R. L., Jurevic, R. J., Guillemette, C., Stoneking, M., Zimmerman, P. A., & Mehlotra, R. K. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.160 · Cited by 70
Pharmacogenetics of Anti-HIV Drugs
Telenti, A., & Zanger, U. M. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094753 · Cited by 70
Self-citationZhang, H., Sridar, C., Kenaan, C., Amunugama, H., Ballou, D. P., & Hollenberg, P. F. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183111 · Cited by 65
Leclerc, J., Tournel, G., Ngangue, E. C.-N., Pottier, N., Lafitte, J., Jaillard, S. M., Mensier, E., Lhermitte, M., Broly, F., & Lo‐Guidice, J. (2009) · Biochimie · doi:10.1016/j.biochi.2009.12.007 · Cited by 63
Martis, S., Mei, H., Vijzelaar, R., Edelmann, L. J., Desnick, R. J., & Scott, S. A. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.48 · Cited by 61
Smith, G. B. J., Bend, J. R., Bedard, L. L., Reid, K. R., Petsikas, D., & Massey, T. E. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1134 · Cited by 61
CYP2B6 and OPRM1 gene variations predict methadone-related deaths
Bunten, H., Liang, W., Pounder, D. J., Seneviratne, C., & Osselton, M. D. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00274.x · Cited by 60
Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.
Ko, J.-W., Desta, Z., & Flockhart, D. A. (1998) · PubMed · Cited by 58
Raccor, B. S., Claessens, A. J., Dinh, J., Park, J. R., Hawkins, D. S., Thomas, S., Makar, K. W., McCune, J. S., & Totah, R. A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039347 · Cited by 58
Ariyoshi, N., Ohara, M., Kaneko, M., Afuso, S., Kumamoto, T., Nakamura, H., Ishii, I., Ishikawa, T., & Kitada, M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039586 · Cited by 57
Exposure to Oral S-ketamine Is Unaffected by Itraconazole but Greatly Increased by Ticlopidine
Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Reponen, P., Turpeinen, M., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.140 · Cited by 56
Clinical impact of patient population differences and genomic variation in efavirenz therapy
King, J. R., & Aberg, J. A. (2008) · AIDS · doi:10.1097/qad.0b013e32830163ad · Cited by 52
Yao, S., Barlow, W. E., Albain, K. S., Choi, J., Zhao, H., Livingston, R. B., Davis, W., Rae, J. M., Yeh, I., Hutchins, L. F., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0281 · Cited by 52
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans
Maimbo, M., Kiyotani, K., Mushiroda, T., Masimirembwa, C. M., & Nakamura, Y. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1118-0 · Cited by 51
Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether
Honda, M., Muroi, Y., Tamaki, Y., Saigusa, D., Suzuki, N., Tomioka, Y., Matsubara, Y., Oda, A., Hirasawa, N., & Hiratsuka, M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040352 · Cited by 50
Das, P. C., Y. Cao, Rose, R. L., Cherrington, N. J., & Hodgson, E. (2008) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2008.23.3-4.237 · Cited by 49
Shah, M. B., Pascual, J., Zhang, Q., Stout, C. D., & Halpert, J. R. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074427 · Cited by 46
Korhonen, L. E., Turpeinen, M., Rahnasto, M., Wittekindt, C., Poso, A., Pelkonen, O., Raunio, H., & Juvonen, R. O. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707173 · Cited by 46
Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2–CYP2B6.28, except CYP2B6.22)
Watanabe, T., Sakuyama, K., Sasaki, T., Ishii, Y., Ishikawa, M., Hirasawa, N., & Hiratsuka, M. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833bba0e · Cited by 42
Radloff, R., Gras, A., Zanger, U. M., Masquelier, C., Arumugam, K., Karasi, J., Arendt, V., Seguin‐Devaux, C., & Klein, K. (2013) · Human Mutation · doi:10.1002/humu.22295 · Cited by 35
Self-citationSistla, J. C., Kumar, S., & Halpert, J. R. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023655 · Cited by 31
Lewis, D. F. V., Lake, B. G., & M. Dickins (2004) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2004.20.3.111 · Cited by 28
Lehr, T., Yuan, J., Hall, D. B., Zimdahl‐Gelling, H., Schaefer, H. G., Staab, A., MacGregor, T. R., & Jayadev, S. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834a522e · Cited by 26
Li, H., Ferguson, S., & Wang, H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065185 · Cited by 22
Melanson, S. E. F., Stevenson, K. E., Kim, H. T., Antin, J. H., Court, M. H., Ho, V. T., Ritz, J., Soiffer, R. J., Kuo, F. C., Longtine, J. A., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21889 · Cited by 21
Successful genotype-tailored treatment with small-dose efavirenz
Gatanaga, H., & Oka, S. (2009) · AIDS · doi:10.1097/qad.0b013e32831940e3 · Cited by 17
Bumpus, N. N., & Hollenberg, P. F. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048637 · Cited by 13
Cited by
BiT age: A transcriptome‐based aging clock near the theoretical limit of accuracy
Meyer, D. H., & Schumacher, B. (2021) · Aging Cell · doi:10.1111/acel.13320 · Cited by 165
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity
Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0685-1 · Cited by 90
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001392 · Cited by 67
Petzold, A., & Hassanin, A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0217956 · Cited by 60
Residual Cdk1/2 activity after DNA damage promotes senescence
Müllers, E., Silva Cascales, H., Burdova, K., Macurek, L., & Lindqvist, A. (2017) · Aging Cell · doi:10.1111/acel.12588 · Cited by 56
Metadata
- Authors
- Zanger, U. M., & Klein, K.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 24-24
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W1987178620
- Cited by
- 345
- References
- 121
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.